Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans

Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.

NCT Number	NCT07177885
Lead Sponsor	University Hospital, Clermont-Ferrand Collaborators: University of the Basque Country (UPV/EHU), Hopital Lariboisière
Conditions	Migraine
Enrollment	144 participants
Start Date	2026-03-05
Primary Completion	2028-03 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-09